Shamburg News · 8-K filed Oct 27, 2026, 8:55 AM EDT

Atrium Therapeutics Doses First Patient in Phase 1/2 Corventis Trial of ATR 1072

RNA · Atrium Therapeutics, Inc.

  • Other event
  • Materiality: medium

On October 27, 2026, Atrium Therapeutics, Inc. announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial evaluating ATR 1072 for the potential treatment of PRKAG2 syndrome. The global trial will enroll approximately 37 participants, and the company expects initial proof-of-concept data in the second half of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-432949.

Written from the filing by Shamburg Markets. Figures are as reported by the company.